Is Wegovy affected by genetics?
Yes. Its active ingredient has published pharmacogenetic guidance for a gene that varies between people.
Wegovy is affected by pharmacogenetics through the GLP1R gene. Your genotype for this gene can change how well Wegovy works for you or how well you tolerate it. The strongest evidence level on this page is Moderate, from the published guidelines shown below.
What's in Wegovy
Semaglutide Affected by GLP1R
Affected by GLP1R. Guidance from Gene2Rx, moderate evidence.
Read the full semaglutide genetics guideHow might your genetics affect Wegovy?
A GLP1R variant is associated with how much weight people lose, and a GIPR variant with nausea and vomiting risk on tirzepatide. Our GLP-1 guide explains what each one means.
Read the GLP-1 genetics guideSemaglutide phenotype recommendations
Published guidance from Gene2Rx on how semaglutide should be dosed or substituted based on your GLP1R phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
| Typical ResponseGLP1R | Your genes point to a typical response to this drug, with average weight loss and side effects. | Gene2Rx Standard dosing and titration are expected to produce an average response. |
Moderate |
| Enhanced Response (heterozygous)GLP1R | You may lose a little more weight on this drug than average. Your chance of nausea or vomiting is also slightly higher. | Gene2Rx Use standard dosing. Counsel on the likelihood of somewhat greater weight loss and slightly higher GI side-effect risk; consider slower titration if early side effects emerge. |
Moderate |
| Enhanced Response (homozygous)GLP1R | You are likely to lose more weight on this drug than average. Your chance of nausea or vomiting is also higher. | Gene2Rx Use standard dosing. Counsel on the likelihood of greater weight loss and higher GI side-effect risk; consider a slower titration schedule to mitigate side effects. |
Moderate |
| IndeterminateGLP1R | We couldn't read your GLP1R gene from your data, so we can't tailor advice for this drug. | Gene2Rx Use standard dosing and titration. Monitor response. |
Not rated |
| Not availableGLP1R | We do not have a GLP1R result for you, so we cannot personalize guidance for semaglutide. | Gene2Rx Use standard dosing and titration. Monitor response. |
Not rated |
Source: Gene2Rx
The gene behind the guidance
GLP1R Glucagon-Like Peptide-1 Receptor
GLP1R is the cell-surface receptor that GLP-1 drugs like semaglutide and tirzepatide bind to. A common variant (rs10305420, Pro7Leu) changes how efficiently the receptor gets made and shipped to the cell surface. Leu7 carriers tend to lose a bit more weight on GLP-1 drugs, but they also get more nausea and vomiting.
About 64% of people of European ancestry carry at least one Leu7 allele, and the allele is less common in other groups (28% Admixed American, 16% East Asian, 7% African). The association was measured most precisely in people of European ancestry. The variant doesn't decide whether a GLP-1 drug will work for someone. It changes how strong the response is and shifts the side-effect profile.
See all drugs affected by GLP1RBrowse the full drug class: Weight management (GLP-1 agonists).
Find out how your genetics affect Wegovy
Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.